Invitrogen and Genoway to Co-Market RNAi Services
Invitrogen and Genoway will co-market RNAi-related services, the companies said last week.
Under the agreement, Invitrogen will combine its expertise in RNAi research technologies with Genoway's portfolio of transgenesis technologies and RNAi in vivo experience to create a new services platform. The platform will allow RNAi vector design through the creation of RNAi transgenic rodent models.
Both companies will share revenues, Genoway said.
Additional details were not disclosed.
NCI RFA Offers $3M for Developing Molecular Technologies
The National Cancer Institute last week allocated nearly $3 million for research on developing cancer-relevant molecular technologies, according to a request for applications published on the National Institutes of Health web site.
NCI said it expects to award between 10 and 15 new and/or competing continuation grants for periods up to two or three years, depending on the award mechanism.
The institute will consider proposals that involve methods and tools to enable research, including instrumentation, techniques, and devices. Molecular technologies are distinct from resources such as databases, individual reagents, therapeutic agents, and tissue repositories, which are not included under this initiative.
The receipt dates for intents are Jan. 23 and April 26. The applications must be received by Feb. 22 and May 26.
TransTech Pharma Selects Genedata's High Throughput Screener
TransTech Pharma signed a multi-year license for Genedata's high throughput screening-analysis software, Genedata said last week.
TransTech Pharma scientists will use the software, Genedata Screener, to enhance their efforts to develop small molecules as therapeutics for treating human diseases.
Screener has been integrated with TransTech Pharma's IT and screening infrastructure to automate data quality evaluation and standardize the analysis of compound bioactivity, Genedata said.
Financial details were not disclosed.